Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Gemphire Therapeutics Raises USD5 Million in Financing Round 11
Gemphire Therapeutics Raises USD5 Million in Series A Financing Round 12
Merger 13
Michigan Life Therapeutics Merges with Gemphire Therapeutics 13
Equity Offering 14
Gemphire Therapeutics Prices Public Offering of Shares for USD22 Million 14
Gemphire Therapeutics Plans to Raise up to USD26 Million in Public Offering of Shares 16
Gemphire Therapeutics Raises USD12.5 Million in Private Placement of Units 17
Gemphire Therapeutics Raises USD30 Million in IPO 18
Gemphire Therapeutics Raises USD1.5 Million in Private Placement of Shares 20
Debt Offering 21
Gemphire Therapeutics Raises USD5 Million in Private Placement of Notes 21
Gemphire Therapeutics Raises USD0.2 Million in Private Placement of Notes 22
Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 23
Gemphire Therapeutics Raises USD2.8 Million in Private Placement of Notes 24
Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 25
Gemphire Therapeutics Inc – Key Competitors 26
Gemphire Therapeutics Inc – Key Employees 27
Gemphire Therapeutics Inc – Locations And Subsidiaries 28
Head Office 28
Recent Developments 29
Financial Announcements 29
Aug 13, 2018: Gemphire Therapeutics reports second quarter 2018 financial results and provides corporate update 29
May 08, 2018: Gemphire Therapeutics Reports First Quarter 2018 Financial Results and Provides Corporate Update 31
Mar 15, 2018: Gemphire Therapeutics Announces Fourth Quarter And Fiscal Year 2017 Financial Results 33
Nov 13, 2017: Gemphire Therapeutics Reports Third Quarter 2017 Financial Results 35
Aug 14, 2017: Gemphire Announces Second Quarter 2017 Financial Results and Provides Corporate Update 37
May 09, 2017: Gemphire Announces First Quarter 2017 Financial Results and Provides Corporate Update 39
Mar 15, 2017: Gemphire Announces Fiscal Year 2016 Financial Results and Provides Corporate Update 41
Corporate Communications 44
May 03, 2018: Gemphire Therapeutics Announces the Appointment of Steven Gullans, Ph.D., as President and Chief Executive Officer 44
May 30, 2017: Gemphire Therapeutics Announces Departure of Its Chief Executive Officer Mina Sooch 45
Mar 29, 2017: Gemphire Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4) 46
Product News 47
02/27/2018: Gemphire Expert Panel Call on Pediatric Nonalcoholic Fatty Liver Disease and NASH to be Rescheduled 47
02/21/2018: Gemphire to Host Expert Panel Call to Discuss Pediatric Nonalcoholic Fatty Liver Disease and NASH 48
Clinical Trials 50
Jan 31, 2018: Gemphire Announces Initiation of Phase 2a Clinical Trial of Gemcabene in Pediatric Non-Alcoholic Fatty Liver Disease 50
Jan 17, 2018: Gemphire Completes Patient Enrollment in INDIGO-1 Trial in Severe Hypertriglyceridemia Patients 52
Dec 21, 2017: Gemphire Therapeutics Announces Initiation of its First NASH Proof-of-Concept Clinical Trial and its Differentiated NASH Program 53
Nov 13, 2017: Gemphire Therapeutics Presents Data at American Heart Association Scientific Sessions Showing that Gemcabene Significantly Reduces Atherogenic Remnant Lipoprotein and LDL-C as Add-on to Statins in a Cardiometabolic Population 55
Oct 23, 2017: Positive Gemcabene Results in Proof-of-Concept Preclinical NASH Study Presented at The Liver Meeting 2017 56
Sep 25, 2017: Gemphire to Present New COBALT-1 Clinical Data at the 2017 FH Global Summit 57
Sep 19, 2017: Gemphire Announces Plans to Advance Gemcabene into Phase 3 Clinical Development 59
Sep 14, 2017: Gemphire to Host Investor Conference Call to Discuss Future Development Plans for Gemcabene 62
Aug 07, 2017: Gemphire Announces Top-Line Data from ROYAL-1 Phase 2b Clinical Trial in Hypercholesterolemic Patients 63
Jun 28, 2017: Gemphire Announces Top-Line Data from COBALT-1 Phase 2b Clinical Trial in HoFH Patients 64
May 01, 2017: Gemphire to Present at ATVB|PVD 2017 Scientific Sessions 66
Mar 21, 2017: Gemphire Therapeutics Announces Presentation at ACC Meeting of Phase 2 Clinical Trial Investigating Effect of Gemcabene on Insulin Sensitization 67
Jan 30, 2017: Gemphire Announces Interim LDL-C Lowering Data from COBALT-1 Phase 2b Clinical Trial 68
Jan 09, 2017: Gemphire Announces Positive Results for Gemcabene in Proof-of-Concept NASH Preclinical Study 70
Jan 05, 2017: Gemphire Therapeutics Provides Clinical Update 71
Appendix 72
Methodology 72
About GlobalData 72
Contact Us 72
Disclaimer 72
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Gemphire Therapeutics Inc, Deals By Therapy Area, 2012 to YTD 2018 9
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Gemphire Therapeutics Raises USD5 Million in Financing Round 11
Gemphire Therapeutics Raises USD5 Million in Series A Financing Round 12
Michigan Life Therapeutics Merges with Gemphire Therapeutics 13
Gemphire Therapeutics Prices Public Offering of Shares for USD22 Million 14
Gemphire Therapeutics Plans to Raise up to USD26 Million in Public Offering of Shares 16
Gemphire Therapeutics Raises USD12.5 Million in Private Placement of Units 17
Gemphire Therapeutics Raises USD30 Million in IPO 18
Gemphire Therapeutics Raises USD1.5 Million in Private Placement of Shares 20
Gemphire Therapeutics Raises USD5 Million in Private Placement of Notes 21
Gemphire Therapeutics Raises USD0.2 Million in Private Placement of Notes 22
Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 23
Gemphire Therapeutics Raises USD2.8 Million in Private Placement of Notes 24
Gemphire Therapeutics Raises USD2.7 Million in Private Placement of Notes 25
Gemphire Therapeutics Inc, Key Competitors 26
Gemphire Therapeutics Inc, Key Employees 27
List of Figures
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Gemphire Therapeutics Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9